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INTRODUCTION

CONCLUSION

Myositis-specific autoantibodies have been beneficial for both diagnostic purposes as well as understanding
the associated clinical phenotypes. Anti-Mi2-antibodies are strongly associated with dermatomyositis (DM) and
1
have hallmark features of cutaneous disease, milder muscle involvement, and an overall positive prognosis .
Identification of typical characteristics of antibody-associated myositis can be helpful for both diagnostic
purposes as well as screening for associated conditions.

The skin ulcerations the patient developed were atypical for anti1
Mi2 associated DM . Research regarding the development of
these ulcerations correlates more with patient’s positivity for
MDA-5 antibodies, which portends more severe disease with
2
worse prognosis . Identification of clinical phenotype of myositisassociated and myositis-specific autoantibodies assists in the
diagnostic workup and management of related conditions. Although
management can be adjusted by the provider when the disease does
not fit the typical phenotype, concerns truly arise with respect to
predicting complications of potentially severe disease such as ILD or
risk of malignancy. This case demonstrates the clinical conundrum
regarding screening and prognostic implications for patients who
demonstrate worrisome features not usually associated with the
patient’s antibody phenotype.

CLINICAL CASE
A 53 year old male who was evaluated in the rheumatology office with increased myalgia after routine exercise,
unintentional weight loss, skin changes, and rash over the bridge of his nose found to have abnormal capillary
nailfold findings. Further workup showed elevated creatine kinase (CK), aldolase, liver function studies, and
positive anti-Mi2 antibody (tested at Arup on a standardized myositis panel), consistent with the diagnosis of
DM. Other contributing factors for myopathy were ruled out with thyroid screen, urine drug screen, vitamin
D level, and viral serologies. For completeness, the patient underwent screening for malignancy and ILD
with computed tomography of his chest/abdomen/pelvis yielding normal results. The patient was started on
prednisone and methotrexate with initial notable clinical improvement. Upon further corticosteroid dose taper
the patient developed profound ulcerations on the dorsal aspects of his metacarpal phalangeal joints, olecranon
processes, and helix of the right ear. As these ulcerations are more characteristic of DM with anti-melanoma
differentiation associated gene 5 antibodies (MDA-5) than anti-Mi2 antibodies, the patient was tested and found
to be negative for the presence of MDA-5 antibodies. His prednisone dose was increased and methotrexate was
continued with subsequent improvement and resolution of these lesions. Mycophenolate mofetil was added to
the patient’s regimen as combination therapy with methotrexate given the aggressive nature of the ulcerative
lesions. Clinically, the cutaneous lesions improved, and he was able to be tapered off of his steroid dosing
without recurrence of ulcerations.
Table 1. Features of Myositis-specific Autoantibodies
Myositis-specific autoantibody

Anti-Mi2+ autoantibodies

Typical Characteristics/Associations

1.	Betterridge Z, McHugh N. Myositis-specific autoantibodies: an important tool to
support diagnosis of myositis. J Intern Med. 2016 Jul:280(1):8-23.
2.	Fiorentino D, Chung L, Zwerner J, Rosen A, Casciola-Rosen L. The mucocutaneous
and sys-temic phenotype of dermatomyositis patients with antibodies to MDA5
(CADM-140): A retro-spective study. J Am Acad Dermatol. 2011 Jul:65(1):25-34.

•	Cutaneous features: Gottron’s papules, helio-trope rash, V-sign and shawl sign rashes,
cuticular overgrowth.
•	Pulmonary features: no typical pulmonary involvement.
•	Typically respond well to immunosuppressive therapy.

Anti-MDA5 autoantibodies
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•	Mucocutaneous features: palmar erythema-tous macules+/-papules with higher likelihood of
cutaneous ulceration. Gum pain, alopecia, mechanic hands, Gottron sign.
• ILD-association, especially rapidly progres-sive lung disease.

Comment: Typical features associated with anti-Mi2+ and anti-MDA5 autoantibodies1,2.
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